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OBJECTIVES We investigated whether elevated levels of circulating monocyte-platelet aggregates (MPA)
can be used to identify patients with acute myocardial infarction (AMI).
BACKGROUND Commonly used blood markers of AMI reflect myocardial cell death, but do not reflect the
earlier pathophysiologic processes of plaque rupture, platelet activation and resultant
thrombus formation. Circulating MPA form after platelet activation.
METHODS In a single center between October 1998 and November 1999, we measured circulating MPA in
a blinded fashion by whole blood flow cytometry in 211 consecutive patients who presented to the
emergency department (ED) with chest pain and were admitted to rule out AMI. Acute
myocardial infarction was diagnosed by a CK-MB fraction greater than three times control.
RESULTS Patients with AMI (n 5 61), as compared with those without AMI (n 5 150), had
significantly higher numbers of circulating MPA (11.6 6 11.4 vs. 6.4 6 3.6, mean 6 SD, p ,
0.0001). After controlling for age, the adjusted odds of developing AMI for patients in the
2nd, 3rd and 4th quartiles of MPA, in comparison with patients in the lowest quartile (odds
ratio 5 1.0), were 2.1 (95% confidence interval [CI]: 0.7, 6.8), 4.4 (95% CI: 1.5, 13.1) and
10.8 (95% CI: 3.6, 32.0), respectively. The number of circulating MPA in patients with AMI
presenting within 4 h of symptom onset (14.4) was significantly greater than those presenting
after 4 h (9.4) and after 8 h (7.0), (p , 0.001). Of the 61 patients with AMI, 35 (57%) had
a normal creatine kinase isoenzyme ratio at the time of presentation to the ED, but had high
levels of circulating MPA (13.3).
CONCLUSIONS Circulating MPA are an early marker of AMI. (J Am Coll Cardiol 2001;38:1002–6) © 2001
by the American College of Cardiology
In the U.S., approximately 1,100,000 individuals per year
have a new or recurrent acute myocardial infarction (AMI). Of
these patients, 25% of men and 38% of women die within one
year of diagnosis (1). Early treatment intervention significantly
reduces morbidity and mortality in AMI (2). New ST-segment
elevation on the surface electrocardiogram is highly suggestive
of AMI, but the prevalence of AMI may be as low as 20%
among patients with new or dynamic ST-segment depression
or T-wave inversion (3). The diagnosis of AMI in patients
presenting without electrocardiographic evidence of ST-
segment elevation relies on the use of markers of myocardial
necrosis. The MB isoform of creatine kinase (CK-MB) and
cardiac troponins are the most common markers of myocardial
necrosis used in the diagnosis of AMI, but they do not appear
in the peripheral circulation until at least 4 h after onset of
injury (2). Furthermore, these markers do not measure the
pathophysiologic processes that result in myocardial necrosis,
namely coronary plaque erosion or rupture, leukocyte and
platelet activation and coronary artery thrombosis (4).
Upon activation, platelets degranulate and adhere to
monocytes, a process mediated by the platelet surface
expression of P-selectin (CD62P) (5,6), which binds to the
constitutively expressed P-selectin glycoprotein ligand-1
(PSGL-1) on monocytes (7). Firm attachment is subse-
quently mediated by monocyte CD11b/CD18-dependent
platelet interactions (8). The measurement of monocyte-
platelet aggregates (MPA) may be a more robust signal of
platelet activation than the detection of surface P-selectin
on individual platelets because degranulated platelets rapidly
lose surface P-selectin in vivo yet continue to circulate (9).
Indeed, the presence of increased circulating leukocyte-
platelet aggregates has been demonstrated in patients with
stable angina (10), unstable angina (11), AMI (12) and in
those undergoing percutaneous coronary interventions (13).
In this observational study, we, therefore, used whole
blood flow cytometry (14) to investigate whether the pres-
ence of elevated levels of circulating MPA is an early marker
of AMI in patients presenting to an emergency department
(ED) with a chief complaint of chest pain.
METHODS
Study population. The protocol was approved by the
Committee for the Protection of Human Subjects in Re-
search at the University of Massachusetts Medical School.
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The study population consisted of 211 consecutive patients
presenting with a chief complaint of chest pain to the ED at
UMass Memorial Medical Center during the period Octo-
ber 1998 to November 1999. Peripheral blood samples were
drawn in the ED at the time of hospital presentation in a
standardized manner by trained technicians.
Diagnostic criteria. A diagnosis of AMI was made when
the serum CK-MB level was greater than three times the
upper limit of normal at our hospital laboratory.
Monoclonal antibodies. Y2/51 (DAKO, Carpinteria,
California) is directed against CD61 (GPIIIa, i.e., it is
platelet-specific) and was purchased conjugated to fluores-
cein isothiocyanate (FITC). MøP9 (Becton Dickinson,
Rutherford, New Jersey) is directed against CD14 on the
monocyte surface and was purchased conjugated to phyco-
erythrin. Y2/51 and MøP9 are murine IgG monoclonal
antibodies. Murine IgG-FITC (DAKO) was used as a
nonspecific binding isotypic control.
MPA. There were no centrifugation, gel filtration, vortex-
ing or stirring steps that could artifactually activate platelets
or monocytes. The first 2 ml of drawn blood was discarded.
Blood was then drawn into a 3.8% sodium citrate Vacu-
tainer (Becton Dickinson, San Jose, California) and imme-
diately (within 10 min) fixed at 4°C for between 10 min and
2 h at a final concentration of 1% formalin (Polysciences,
Warrington, Pennsylvania) and 1.5X Hanks Balanced Sa-
line solution concentrate (GIBCO, Grand Island, New
York). This duration of fixation does not result in artifactual
platelet activation. Once fixed, the samples are stable for up
to 48 h (data not shown). The samples were then incubated
at 22°C for 10 min with saturating concentrations of the
monoclonal antibodies Y2/51-FITC (GPIIIa-specific) and
MøP9-PE (CD14-specific) and then diluted fivefold with
distilled H2O, vortexed and incubated at 22°C for 10 min
(to lyse the red blood cells). Two volumes of phosphate-
buffered saline, pH 7.4, were added to bring the final blood
dilution to 1:33 (to reduce monocyte/platelet coincidence).
The samples were placed on ice until analysis within 4 h by
flow cytometry (with low-flow setting) in a FACSCalibur
flow cytometer (Becton Dickinson) equipped with a 488 nm
argon ion laser, standard three-color filter configuration and
CELLQuest cell analysis software (Becton Dickinson).
Fluorescence output was standardized daily using SPHERO
Rainbow Calibration Particles (Spherotech, Libertyville,
Illinois). Monocytes were identified by their brightly posi-
tive CD14 expression on a two-parameter dot plot display-
ing linear orthogonal light scatter vs. MøP9-PE (FL2). The
threshold was set on forward angle light scatter to include all
monocytes and exclude debris and uncomplexed platelets.
The percentage of MPA was identified in single parameter
histograms of Y2/51-FITC (FL1) fluorescence displaying
events from the monocyte gate. The positive analysis region
was determined using an IgG-FITC conjugated isotypic
control. A minimum of 2,000 monocytes was counted per
test.
Statistical analysis. Differences in patient demographic
and medical history characteristics between those with
AMI and those with chest pain not attributable to AMI
were compared using chi-square and Student t tests of
statistical significance for categorical and continuous
variables, respectively. Analysis of variance was used to
perform multiple data comparisons using Bonferroni’s
method of correction of average number of MPA as well as
to test for differences in MPA between the AMI and
non-AMI comparison groups. To control for the potentially
confounding influence of age and other covariates (includ-
ing past medical history and concomitant medications), we
carried out a logistic regression analysis to examine the
association between the occurrence of AMI and MPA. A
Pearson correlation coefficient was used to measure the
relationship between the duration of acute coronary symp-
toms and the level of MPA in AMI patients.
RESULTS
Baseline characteristics. There were no significant differ-
ences between patients with (n 5 61) and without (n 5
150) confirmed AMI with respect to age, gender, history of
hypertension, stable angina, unstable angina, AMI, diabe-
tes, hyperlipidemia and use of tobacco, beta-adrenergic
blocking agents, calcium antagonists and angiotensin-
converting enzyme inhibitors (Table 1).
Circulating MPA. Of patients presenting to the ED with
chest pain, those with AMI (n 5 61), as compared with
those without AMI (n 5 150), had significantly higher
numbers of circulating MPA (11.6 6 11.4 vs. 6.4 6 3.6,
mean 6 SD, p , 0.0001) (Fig 1). The median number
(with 25th/75th percentiles) of circulating MPA in patients
with AMI as compared with those without AMI was 8.7
(6.3/13.1) vs. 5.4 (4.3/7.1). Moreover, patients with AMI
had significantly higher numbers of circulating MPA than
patients discharged with a diagnosis of unstable angina (n 5
39) (11.6 6 11.4 vs. 5.5 6 2.6, mean 6 SD, p , 0.001).
The median number (with 25th/75th percentiles) of circu-
lating MPA in patients with AMI as compared with those
with a discharge diagnosis of unstable angina was 8.7
(6.3/13.1) vs. 4.8 (4.1/6.1).
After controlling for age and nitrate use, patients with
AMI still had a significantly higher number of circulating
MPA than patients without AMI (p , 0.001). After
controlling for age, the adjusted odds of developing
AMI for the 2nd, 3rd and 4th quartiles of MPA, in
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CI 5 confidence interval
CK-MB 5 creatine kinase isoenzyme
ED 5 emergency department
FITC 5 fluorescein isothiocyanate
MPA 5 monocyte-platelet aggregates
PSGL-1 5 P-selectin glycoprotein ligand-1
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comparison with patients in the lowest quartile (odds
ratio 5 1.0), were 2.1 (95% confidence interval [CI]: 0.7,
6.8), 4.4 (95% CI: 1.5, 13.1) and 10.8 (95% CI: 3.6, 32.0),
respectively (Table 2).
To assess whether MPA are an early marker of myocar-
dial infarction, we compared the levels of MPA in patients
with confirmed AMI presenting within 4 h of symptom
onset with those presenting after 4 h and after 8 h of chest
pain. The number of circulating MPA in patients with AMI
presenting within 4 h of acute coronary symptoms (14.4 6
16.6) was significantly higher than those presenting after 4 h
(9.4 6 4.5, p , 0.001) and after 8 h (7.0 6 3.6, p , 0.001)
(Fig. 2).
Of the 61 patients with AMI, 35 (57%) had a normal
CK-MB ratio (0 to 2.3) at the time of presentation to the
ED but high levels of circulating MPA (13.3 6 14.6)
(Fig. 3).
DISCUSSION
Our study demonstrates that, of patients presenting to an
ED with chest pain, those with AMI have higher numbers
of circulating MPA than those without AMI. Furthermore,
MPA appear in the peripheral circulation earlier than
routine markers of myocardial necrosis, such as CK-MB.
Markers of myocardial cell death and MPA in AMI. A
rise and fall in serum cardiac enzymatic markers in patients
presenting with chest pain satisfies one of the criteria set by
the World Health Organization for the diagnosis of AMI
(15). After myocardial cell injury, myoglobin may appear in
the peripheral circulation as soon as 1 h, creatine kinase and
its MB-isoform within 4 h to 6 h and cardiac troponins
within 4 h to 12 h (2). In this study, elevated levels of
circulating MPA appeared in the blood before CK-MB.
Indeed, the levels of circulating MPA were highest in
patients with AMI who did not yet have elevated levels of
CK-MB at the time of presentation.
Although serum cardiac markers reflect evidence of myo-
cardial necrosis, they provide no information about the
pathophysiologic state within the coronary artery. In con-
trast, circulating P-selectin/PSGL-1-dependent MPA may
reflect platelet activation caused by intracoronary plaque
disruption, fissuring or erosion. Thus, MPA may be a
marker of plaque instability and provide information on the
intracoronary dynamics of thrombosis and inflammation.
Plaque rupture and thrombus formation are characteristic of
the acute coronary artery syndromes of unstable angina,
non–Q-wave myocardial infarction and Q-wave myocardial
Figure 1. Monocyte-platelet aggregates in the peripheral circulation of
patients presenting to an emergency department with chest pain. Data are
mean 6 SD. AMI 5 acute myocardial infarction.
Figure 2. Monocyte-platelet aggregates in the peripheral circulation of
patients with acute myocardial infarction with respect to the duration of
symptoms. Data are mean 6 SD.
Table 2. Adjusted Odds of Developing AMI According to
Levels of Circulating Monocyte-Platelet Aggregates
Quartile Odds Ratio 95% CI
1 1 —
2 2.1 0.7, 6.8
3 4.4 1.5, 13.1
4 10.8 3.6, 32
AMI 5 acute myocardial infarction; CI 5 confidence interval.
Table 1. Baseline Characteristics
AMI
(n 5 61)
No AMI
(n 5 150)
p
Value
Age (mean) 56 58 NS
Men 67% 67% NS
Prior stable angina 14% 12% NS
Prior unstable angina 33% 25% NS
Prior AMI 29% 27% NS
Prior CHF 3% 10% NS
Valvular heart disease 0% 7% NS
Hypertension 60% 63% NS
Hyperhcolesterolemia 33% 22% NS
Current tobacco use 11% 21% NS
Family history of CAD 11% 24% NS
Diabetes 23 15% NS
Current medications
Aspirin 9% 17% NS
Beta-blocker 10% 18% NS
Nitrates 55% 15% , 0.05
Calcium antagonists 5% 11% NS
ACE inhibitor 11% 12% NS
ACE 5 angiotensin-converting enzyme; AMI 5 acute myocardial infarction;
CAD 5 coronary artery disease; CHF 5 congestive heart failure.
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infarction (4). However, the degree of thrombus formation
is greater and the composition of the thrombus different in
patients with myocardial infarction than it is in those with
unstable angina (16). Indeed, in our study, patients with
AMI had significantly higher numbers of circulating MPA
than patients with unstable angina.
While the formation of MPA is platelet P-selectin-
dependent (5,6), the detection of platelet surface P-selectin
may not be the most sensitive marker of platelet activation,
because degranulated platelets rapidly lose surface P-selectin
in vivo yet continue to circulate (9). Therefore, detection of
circulating MPA may be a more robust signal of platelet
activation than platelet surface P-selectin.
Pathophysiologic relevance of MPA. Platelet adhesion to
monocytes is mediated by the platelet surface expression of
P-selectin (5,6), which binds to the constitutively expressed
PSGL-1 on monocytes (7,17,18). Because platelets are in-
volved in both inflammation and thrombosis (19–23), the
formation of MPA may represent targeting of both cell types
to specific inflammatory or thrombotic sites (22,24,25). More-
over, adherence of platelets to monocytes has been shown to
regulate various monocyte actions. For example, platelets
supply cholesterol to monocytes (26) that may then mature
into lipid-laden macrophages characteristic of coronary athero-
sclerosis (27). Additionally, platelet surface P-selectin induces
the expression of tissue factor on monocytes (28) and promotes
fibrin deposition (24) within a growing thrombus at sites of
vascular injury. Furthermore, the binding of thrombin-
stimulated platelets induces monocyte cytokine expression
(12), and monocyte chemokine synthesis can be regulated by
platelet surface P-selectin in concert with the platelet chemo-
kine RANTES (29). It has been recently shown that activated
platelets express CD40 ligand (CD40L, CD154) on their
surface (30). Binding of CD40L to CD40 on monocytes leads
to monocyte activation and production of cytokines including
interleukin-6 (31), which is associated with unstable angina
(32) and often parallels elevations in C-reactive protein (33).
Elevation of C-reactive protein is, in turn, associated with
acute coronary syndromes including AMI (34).
Study limitations. This study was performed at a single
center with expertise in the use of flow cytometry to study
platelet function. Appropriate caution needs to be exercised
in the interpretation of the data given because: 1) there was
a relatively small number of patients studied; 2) there were
difficulties in accurately identifying the exact time of onset
of acute coronary symptoms; and 3) different results could
be found in a sample population with a different prevalence
of AMI. A large, multicenter study is, therefore, needed to
confirm that high numbers of circulating MPA are an early
marker of AMI. The detection of circulating MPA cur-
rently requires the use of expensive equipment and skilled
technical staff. However, the development of a point-of-care
device for the measurement of circulating MPA is feasible
and would be advantageous. Future studies should investi-
gate if there is any relationship between infarct size and the
number of circulating MPA.
Conclusions. Circulating MPA are an early marker of
AMI.
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